Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oxford Catalysts Selected for Design of 1,100 bpd BTL Plant

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Company has been selected as the Fischer-Tropsch (FT) technology provider for the design and possible construction of a commercial Biomass-to-Liquids (BTL) plant.

The BTL project was recently awarded a $4.1 million grant from the US Department of Defense (under the Defense Production Act Title III Advanced Drop-in Biofuel Production Project), which will help fund detailed engineering for a 1,100 barrels per day (bpd) BTL facility, following which the project will have an opportunity to apply for a further grant of up to $70 million to construct the proposed plant.

The proposed BTL facility, led by Red Rock Biofuels, a subsidiary of IR1 Group LLC (“IR1”), an experienced biofuels project developer, will be located in Oregon and will be designed to convert some 170,000 tons per year of forestry derived biomass into approximately 1,100 bpd of liquid transportation fuels. Preliminary engineering is complete, and with the aid of this grant is expected to be progressing through detailed engineering and design over the course of some nine months. Following successful completion of the detailed design phase, IR1 expects to apply for the additional grant funding to support construction.

Roy Lipski, CEO of Oxford Catalysts Group, said:
“We are pleased to have our technology selected once again, this time for a promising opportunity in the growing area of Biomass-to-Liquids. We’re also excited by the potential for this project to access $70 million of government funding to support early adoption of a synthetic fuels plant.”

Terry Kulesa, CEO of IR1 Group, said:
“The choice of Velocys FT was easy. No other FT technology offered the combination of high performance and efficiency at a scale appropriate for a BTL facility. We’re pleased to be working with the Group on this pioneering project.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!